Arrhythmias & electrophysiology
Orally Inhaled Flecainide for Conversion of Atrial Fibrillation to Sinus Rhythm: INSTANT Phase 2 Trial
Authors' conclusion
The risk-benefit of orally inhaled FlecIH for acute cardioversion of recent-onset AF appears favorable.
Study context
- Population
- Patients with recent-onset (≤48 hours) symptomatic atrial fibrillation (AF)
- Participants
- 98 patients
- Outcome
- Conversion of AF to sinus rhythm
Methodological detailsmulticentre, open-label
- Multicentre
- Open-label
Main finding
As reported in the abstract
90 minutes
Conversion rate
42.6%
95% CI 33.0%–52.6%
Median time to conversion
14.6 minutes
Further findings
Conversion rate, subpopulation excluding predose flecainide exposure for current AF episode
- Conversion rate
- 46.9% (95% CI: 36.4%-57.7%)
Time to discharge and AF recurrence among converters · day 5
- Median time to discharge among converters
- 2.5 hours
- Patients with AF recurrence by day 5
- 2
Electrical cardioversion in non-converters · day 5
- Conversion-no patients undergoing electrical cardioversion by day 5
- 44 (81.5%)
Safety
Adverse events
- Most common AEs related to oral inhalation (eg, cough, oropharyngeal irritation/pain), mostly mild and of limited duration
Original publication
Orally Inhaled Flecainide for Conversion of Atrial Fibrillation to Sinus Rhythm: INSTANT Phase 2 Trial. JACC Clin Electrophysiol. Published 10 April 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →